Reduction in circulating dsDNA antibody titer after administration of LJP 394

Journal of Rheumatology

Volumn 24, Issue 2, 1997, Pages 314-318

  Weisman, Michael H ^a,b,e   Bluestein, Harry G ^a,c   Berner, Cecile M ^a,b   De Haan, Hans A ^a,d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Department of Medicine ^*

^c UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^d La Jolla Pharmaceutical Company   (United States)

^e UCSD MEDICAL CENTER   (United States)

Author keywords

anti dsDNA antibodies; B cell; LJP 394; SLE; systemic lupus erythematosus; tolerance

Indexed keywords

ABETIMUS; ALCLOMETASONE DIPROPIONATE; DNA ANTIBODY; DOUBLE STRANDED DNA; HYDROXYCHLOROQUINE; OLIGONUCLEOTIDE; PREDNISONE; UNCLASSIFIED DRUG;

ADULT; ANTIBODY TITER; ARTICLE; CASE REPORT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HEADACHE; HUMAN; INSOMNIA; INTRAVENOUS DRUG ADMINISTRATION; PRIORITY JOURNAL; RASH; SYSTEMIC LUPUS ERYTHEMATOSUS;

ADULT; ANTIBODIES, ANTINUCLEAR; DEMOGRAPHY; DNA; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MIDDLE AGED; OLIGONUCLEOTIDES; PARTIAL THROMBOPLASTIN TIME; PROTHROMBIN TIME; SEVERITY OF ILLNESS INDEX;

EID: 0031055675     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. Seleznick MJ, Fries JF: Variables associated with decreased survival in systemic lupus erythematosus. Semin Arthritis Rheum 1991;21:73-80.
2. Klippel JH: Curing lupus - views from the foothills. Ann Rheum Dis 1994;53:785-6.
3. Donadio JV, Glassock RJ: Immunosuppressive drug therapy in lupus nephritis. Am J Kidney Dis 1993;21:239-50.
4. Morimoto C, Sano H, Abe T, Homma M, Steinberg AD: Correlation between clinical activity of systemic lupus erythematosus and the amount of DNA in DNA/anti-DNA antibody immune complexes. J Immunol 1982;139:1960-5.
5. Foster MH, Cizman B, Madaio MP: Nepritogenic autoantibodies in systemic lupus erythematosus. Lab Invest 1993;69:494-507.
6. ter Borg EJ, Horst G, Hummel EJ, Limburg C, Kallenberg CGM: Measurement of increases in anti-double stranded DNA antibody levels as a predictor of disease exacerbation in systemic lupus erythematosus. Arthritis Rheum 1990;33:634-43.
7. Bootsma H, Spronk P, Derksen R, et al: Prevention of relapses in systemic lupus erythematosus. Lancet 1995;345:1595-9.
8. Plunkett ML, Ivcrson GM, Crisologo J, et al. LJP 394: A novel clinical candidate for the treatment of lupus nephritis. Lupus 1995;(suppl 2)4:S99.
9. Coutts SM, Plunkett ML, Iverson GM, Barstad PA, Berner CM: Pharmacological intervention in antibody mediated disease. Lupus (in press).
10. Tan EM, Cohen AS, Fries JF, et al: The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982;25:1271-7.
11. Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH: Derivation of the SLEDAI: A disease activity index for lupus patients. Arthritis Rheum 1992;35:630-40.
12. Jones DS, Barstad PA, Field MJ: Immunospecific reduction of antioligonucleotide antibody-forming cells with a tetrakisoligonucleotide conjugate (LJP 394), a therapeutic candidate for the treatment of lupus nephritis. J Med Chem 1995;38:2138-44.